Researchers map a brain switch that can drive weight loss in two opposite ways
Cambridge scientists found that a single brain receptor can trigger weight loss two opposite ways in mice, a preclinical clue that could shape future drug combinations, though it has not been tested in people [1].
Researchers at the University of Cambridge's Institute of Metabolic Science say they have solved a puzzle about a brain receptor called GIPR: why turning it on and turning it off can both lead to weight loss. The study, published in Nature Metabolism, was done in mice, not people [1].
The receptor in question is the glucose-dependent insulinotropic polypeptide receptor, or GIPR. Some approved drugs, including Mounjaro and Zepbound, activate GIPR. Other experimental treatments, such as MariTide, block it instead. Both strategies can produce weight loss, and until now it was not clear how opposite actions on the same receptor could reach a similar result [1].
Using mice genetically engineered to lack GIPR in specific brain regions, the Cambridge team traced the two effects to two different locations. Activating GIPR in the brainstem, an area involved in appetite and nausea, reduced how much the mice ate and lowered their body weight. Blocking GIPR in the hypothalamus, a region that regulates hunger, worked through a different route: it removed what the researchers describe as a 'brake' on fullness signals, letting those signals act more strongly on the brainstem [1].
The team also reported that blocking GIPR appeared to boost the effect of experimental drugs that target the amylin receptor, a separate hormone pathway involved in appetite. That finding suggests GIPR-blocking compounds might eventually be paired with other drug classes, not just GLP-1 medicines, to increase weight loss [1]. Study author Dr. Jo Lewis said understanding which brain circuits respond to these medications could help researchers design drugs that produce more weight loss with fewer side effects, and that could work in combination with other obesity medicines to greater effect [1].
Why it matters for patients
This research does not change anything about currently available treatments. Ozempic, Wegovy, Mounjaro, and Zepbound remain approved based on human trial data already reviewed by regulators, and this mouse study does not add new safety or effectiveness information about those drugs for people [1].
What the finding does is offer scientists a possible explanation for why drugs with opposite actions on GIPR, like Mounjaro's activation versus MariTide's blocking, can both help with weight loss. That kind of mechanistic clue is part of a broader effort in 2026 to separate the appetite-suppressing effects of GLP-1 biology from effects on energy expenditure, with the hope of eventually reducing the nausea and other gastrointestinal side effects that limit some patients' ability to stay on current drugs [1].
For now, this is preclinical brain-circuit mapping in mice. It has not been tested in humans, and there is no timeline in the source material for when, or whether, this insight might lead to a new drug or a new combination therapy reaching clinical trials [1].
What happens next
The sources do not describe specific next steps, such as planned human trials targeting these brain circuits. MariTide, which combines GIPR blocking with GLP-1 receptor activation, is already in phase 3 clinical trials, and the Cambridge findings are described as helping explain why that combination approach can work, though no new trial dates tied to this particular study are given [1].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.